Outcome of the Board meeting held on 23rd May, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Oxygenta Pharmaceutical Limited held its Board Meeting on 23rd May, 2026 and approved audited financial results for FY 2025-26. The company reported total revenue of Rs. 11,326.77 lakhs (up from Rs. 11,060.77 lakhs in previous year), but loss before tax widened significantly to Rs. 2,218.02 lakhs from Rs. 1,435.14 lakhs. Net loss stood at Rs. 1,757.17 lakhs vs Rs. 1,029.83 lakhs previously. The balance sheet shows negative equity of Rs. 4,268.68 lakhs with total borrowings of Rs. 10,956.68 lakhs. The board also appointed two additional directors — Mr. Amireddy Venkatesu Reddy (Executive category, 3 years) and Mr. Janardhana Reddy Yeddula (Independent category, 5 years). Both appointees are associated with the holding company, Virupaksha Organics Limited, which acquired 56.5% stake in June 2025 making Oxygenta its subsidiary. M/s. Suryachandra & Associates was appointed as Internal Auditor for FY 2026-27.
The company continues to burn cash with widening losses and negative net worth. The appointment of two directors linked to the promoter holding company raises governance concerns about board independence. Investors should monitor the upcoming shareholder approvals for these appointments and the company's path to profitability.